IL305095A - Use of a HER2-targeted antibody-drug conjugate in the treatment of specific breast cancer - Google Patents

Use of a HER2-targeted antibody-drug conjugate in the treatment of specific breast cancer

Info

Publication number
IL305095A
IL305095A IL305095A IL30509523A IL305095A IL 305095 A IL305095 A IL 305095A IL 305095 A IL305095 A IL 305095A IL 30509523 A IL30509523 A IL 30509523A IL 305095 A IL305095 A IL 305095A
Authority
IL
Israel
Prior art keywords
antibody
seq
breast cancer
use according
amino acid
Prior art date
Application number
IL305095A
Other languages
English (en)
Hebrew (he)
Original Assignee
Remegen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remegen Co Ltd filed Critical Remegen Co Ltd
Publication of IL305095A publication Critical patent/IL305095A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL305095A 2021-02-18 2022-02-17 Use of a HER2-targeted antibody-drug conjugate in the treatment of specific breast cancer IL305095A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110189905 2021-02-18
CN202110506596 2021-05-10
PCT/CN2022/076554 WO2022174775A1 (en) 2021-02-18 2022-02-17 Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer

Publications (1)

Publication Number Publication Date
IL305095A true IL305095A (en) 2023-10-01

Family

ID=82931194

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305095A IL305095A (en) 2021-02-18 2022-02-17 Use of a HER2-targeted antibody-drug conjugate in the treatment of specific breast cancer

Country Status (11)

Country Link
US (1) US20240148894A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294455A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506708A (cg-RX-API-DMAC7.html)
KR (1) KR20230146526A (cg-RX-API-DMAC7.html)
CN (1) CN117460538A (cg-RX-API-DMAC7.html)
AU (1) AU2022222937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206798A1 (cg-RX-API-DMAC7.html)
IL (1) IL305095A (cg-RX-API-DMAC7.html)
MX (1) MX2023009376A (cg-RX-API-DMAC7.html)
TW (1) TW202241523A (cg-RX-API-DMAC7.html)
WO (1) WO2022174775A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
EP4676543A1 (en) * 2023-03-10 2026-01-14 Seagen Inc. Methods of treating cancer using anti-her2 antibody-drug conjugates and her2 kinase inhibitors
WO2025054918A1 (en) * 2023-09-14 2025-03-20 Remegen Co., Ltd. Methods of treating cancer using anti-her2 antibody-drug conjugates and anti-pd-1 antibodies
WO2025054916A1 (en) * 2023-09-14 2025-03-20 Remegen Co., Ltd. Methods of treating cervical cancer using anti-her2 antibody-drug conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3480215T (pt) * 2013-11-19 2021-07-05 Remegen Ltd Anticorpo anti-her2 e seu conjugado
US10689458B2 (en) * 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
SG11202104269PA (en) * 2019-03-26 2021-05-28 Remegen Co Ltd Anti-her2 antibody drug conjugate pharmaceutical preparation

Also Published As

Publication number Publication date
TW202241523A (zh) 2022-11-01
JP2024506708A (ja) 2024-02-14
AU2022222937A9 (en) 2024-07-18
EP4294455A1 (en) 2023-12-27
CN117460538A (zh) 2024-01-26
CA3206798A1 (en) 2022-08-25
WO2022174775A1 (en) 2022-08-25
US20240148894A1 (en) 2024-05-09
MX2023009376A (es) 2023-08-17
EP4294455A4 (en) 2025-12-31
AU2022222937A1 (en) 2023-08-17
KR20230146526A (ko) 2023-10-19

Similar Documents

Publication Publication Date Title
US20240148894A1 (en) Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
AU2017264959B2 (en) Methods of treating skin cancer by administering a PD-1 inhibitor
Dobrenkov et al. GD2-targeted immunotherapy and radioimmunotherapy
US20240209090A1 (en) Anti-pd-1 antibodies for treatment of lung cancer
US20240207424A1 (en) Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer
US20240207431A1 (en) Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer
WO2019173523A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
TW202122114A (zh) 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
JP2022527334A (ja) 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
Fiedler et al. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
WO2018187158A1 (en) Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents
WO2023218378A1 (en) Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
CN116209468A (zh) 使用抗cd73和抗pd-l1抗体和化疗的治疗方法
HK40104997A (en) Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
HK40109224A (en) Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer
JP7817242B2 (ja) 鼻咽頭癌の治療における抗pd-1抗体の使用
WO2023227115A1 (en) A method of treating solid tumor
TW202615102A (zh) 抗體藥物偶聯物用於治療癌症的方法
HK40118859A (en) Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
HK40098919A (en) Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
HK40108053A (en) Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer